Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported first-quarter sales of $677.7 million, up 34% year over year, beating the consensus of $623.9 million.
週三，聯合療法公司（納斯達克股票代碼：UTHR）公佈的第一季度銷售額爲6.777億美元，同比增長34％，超過預期的6.239億美元。
The company reported EPS of $6.17, up from $4.86 a year ago, surpassing the consensus of $5.56.
該公司公佈的每股收益爲6.17美元，高於去年同期的4.86美元，超過了預期的5.56美元。
"The first quarter of 2024 represents another quarter of record revenue and double-digit year-over-year revenue growth," jointly said Martine Rothblatt, Chairperson and Chief Executive Officer and Michael Benkowitz, President and Chief Operating Officer.
董事長兼首席執行官瑪蒂娜·羅斯布拉特和總裁兼首席運營官邁克爾·本科維茨共同表示：“2024年第一季度是收入創紀錄的又一個季度，收入同比增長兩位數。”
"That growth, coupled with our upcoming clinical reads, puts us in a unique position in the biotech industry: a company with a solid and growing commercial foundation, near-term clinical catalysts, and the potential to provide an unlimited supply of tolerable, transplantable organs."
“這種增長，加上我們即將發佈的臨床數據，使我們在生物技術行業處於獨特的地位：一家擁有堅實且不斷增長的商業基礎、短期臨床催化劑以及無限量供應可耐受的可移植器官的公司。”
"Our distinctive commercial and clinical profile, alongside our solid balance sheet and cash flow potential, makes United Therapeutics a compelling investment opportunity," said James Edgemond, Chief Financial Officer and Treasurer. "That's why we implemented a $1 billion accelerated share repurchase that concretely demonstrates our belief in our near-term and long-term potential despite potential competition emerging this year."
首席財務官兼財務主管詹姆斯·埃奇蒙德表示：“我們獨特的商業和臨床概況，加上我們穩健的資產負債表和現金流潛力，使聯合療法成爲一個引人注目的投資機會。”“這就是爲什麼我們實施了10億美元的加速股票回購，這具體表明瞭儘管今年出現了潛在的競爭，但我們對短期和長期潛力的信念。”
Tyvaso revenues grew by 56% to $372.5 million, primarily due to an increase in quantities sold and continued growth in commercial utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to some extent, due to price increases.
Tyvaso收入增長了56％，達到3.725億美元，這主要是由於銷售量的增加以及與間質性肺病相關的肺動脈高壓患者的商業利用率持續增長，在某種程度上也是由於價格上漲所致。
Tyvaso DPI revenues increased 92% to $227.5 million. Nebulized Tyvaso sales reached $145 million, up 21%.
Tyvaso DPI 收入增長了 92%，達到 2.275 億美元。Nebulized Tyvaso的銷售額達到1.45億美元，增長了21％。
Orenitram sales increased 20% to $106.2 million and Unituxin sales reached $58.4 million, up 19%.
Orenitram的銷售額增長了20％，達到1.062億美元，Unituxin的銷售額達到5,840萬美元，增長了19％。
The company highlighted that it reported the highest quarterly revenue for Tyvaso, Orenitram, and Unituxin.
該公司強調，其公佈的Tyvaso、Orenitram和Unituxin的季度收入最高。
Price Action: UTHR shares are up 8% at $253.08 at the last check Wednesday.
價格走勢：在週三的最後一次檢查中，UTHR股價上漲了8％，至253.08美元。
譯文內容由第三人軟體翻譯。